Tumor necrosis factor or tumor promoting factor?

Cytokine and Growth Factor Reviews

Volumn 13, Issue 2, 2002, Pages 135-141

  Balkwill, Fran ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

Cancer; Carcinogenesis; Inflammation; TNF; Tumor promotion

Indexed keywords

ANGIOGENIC FACTOR; CD8 ANTIGEN; CELECOXIB; CENTOCOR; ETANERCEPT; IMMUNEX; INFLIXIMAB; MATRIX METALLOPROTEINASE; MELPHALAN; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR; THALIDOMIDE; TUMOR NECROSIS FACTOR; TUMOR PROMOTER; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANIMAL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER GROWTH; CANCER MODEL; CANCER PREVENTION; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL DEATH; CELL KILLING; CELL SURVIVAL; CLINICAL TRIAL; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; DISEASE MODEL; DNA DAMAGE; DRUG MECHANISM; GENETICS; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; METASTASIS; MOUSE; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PHYSIOLOGY; PROTEIN INDUCTION; SHORT SURVEY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC MOUSE; TUMOR CELL; TUMOR PROMOTION; REVIEW;

ANIMALIA; MUS MUSCULUS;

ANIMALS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; MICE; MICE, TRANSGENIC; NEOPLASM TRANSPLANTATION; NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036005888     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(01)00020-X     Document Type: Short Survey

References (89)

1. The role of tumor necrosis factor in health and disease
2. The TNF and TNF receptor superfamilies: Integrating mammalian biology
3. The treatment of malignant tumors by repeated inoculations of erysipelas: With a report of ten original cases
4. An endotoxin-induced serum factor that causes necrosis of tumours
5. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin
6. Clinical applications of TNF-a in cancer
7. Inflammation and cancer: Back to Virchow
8. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease
9. Late results of the treatment of inoperable sarcoma by the mixed toxins of erysipelas and bacillus prodigiosus
10. Human tumour xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons
11. Immunomodulatory properties of recombinant murine and human tumor necrosis factor
12. Synergistic cytotoxic and antitumour effects of recombinant tumour necrosis factor and hyperthermia
13. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in Meth-A fibrosarcomas
14. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor
15. Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis
16. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity
17. The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endoxin-induced hemorrhagic necrosis and regression of an established sarcoma
18. Evidence for the involvement of endothelial cell integrin aVb3 in the disruption of the tumor vasculature induced by TNF and IFN-γ
19. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: A histopathological, immunohistochemical and electron microscopical study
20. Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
21. TNF-a augments intratumoural concentrations of doxorubicin in TNF-a-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
22. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity
23. Possible relationships between in vivo antitumour activity and toxicity of tumour necrosis factor alpha
24. Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK-cells
25. The p55 TNF-a receptor plays a critical role in T-cell alloreactivity
26. Crucial role of TNF-a in CD8 cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo
27. Compromised anti-tumor responses in tumor necrosis factor-a knockout mice
28. Tumour necrosis factor in man: Clinical and biological observations
29. A phase 1 clinical trial of recombinant human tumor necrosis factor
30. Isolated limb perfusion with high-dose tumor necrosis factor-a in combination with interferon-g and melphalan for nonresectable extremity soft tissue sarcomas: A multicenter trial
31. Tumor necrosis factor and its receptors in human ovarian cancer
32. Expression of tumour necrosis factor (TNFa) and its receptors in benign and malignant breast tissue
33. Association between tumor necrosis factor in serum and cachexia in patients with prostate cancer
34. Expression of interleukin-1b and tumour necrosis factor-a in plasma cells from patients with multiple myeloma
35. Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease
36. Influence of hypoxia and glucose deprivation on tumour necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor expression in human cultured monocytes
37. Tumor necrosis factor-a represses androgen sensitivity in the LNCaP prostate cell cancer line
38. Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients
39. TNF receptors in chronic lymphocytic leukemia
40. Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: Correlation with clinical and biological features and outcome
41. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alfa-2b in chronic myelogenous leukemia
42. Paradoxical, effects of tumour necrosis factor in experimental ovarian cancer
43. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice
44. Enhancement of experimental metastasis by tumor necrosis factor
45. Cytokines in non-genotoxic hepatocarcinogenesis
46. IL-18 regulates IL-1b-dependent hepatic melanoma metastasis via vascular cell adhesion molecule-1
47. Soluble tumor necrosis factor receptor type 1 enhances tumor development and persistence in vivo
48. Tumour necrosis factor-a deficient mice are resistant to skin carcinogenesis
49. Essential role of tumor necrosis factor a (TNF-a) in tumor promotion as revealed by TNF-a-deficient mice
50. Inhibition of pro-inflammatory cytokine gene expression and papilloma growth during murine multistage carcinogenesis by pentoxifylline
51. Tumor necrosis factor-a enhanced tumorigenesis is associated with an angiogenic switch during tumor promotion
52. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (GLD) phenotype
53. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice
54. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation
55. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism
56. Nitric oxide synthase activity in human gynecological cancer
57. Metabolic competence and susceptibility of intestinal epithelium to genotoxic injury during regeneration
58. Tumor necrosis factor A as an autocrine and paracrine growth factor for ovarian cancer: Monokine induction of tumor cell proliferation and tumor necrosis factor A expression
59. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFa and IL-1a
60. Induction of vascular endoehtlial growth factor by tumor necrosis factor a in human glioma cells
61. Inflammatory cytokines induce endothelial cells to produce and release basic fibroblast growth factor and to promote Kaposi's sarcoma-like lesions in nude mice
62. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis
63. Hypoxia down-regulates MCP-1 expression: Implications for macrophage distribution in tumors
64. Regulation of moncyte MMP-9 production by TNF-a and a tumour-derived soluble factor (MMPSF)
65. Association of tumour necrosis factor alpha and its receptors with thymidine phosphorylase expression in invasive breast carcinoma
66. Tumor necrosis factor induces genes involved in inflammation, cellular and tissue repair, and metabolism in murine fibroblasts
67. Comparative effects of interleukin-1 and tumor necrosis factor-a on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts
68. TNF-a stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression
69. Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome
70. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment
71. Frequent genotype changes at -308 and 488 regions of the tumor necrosis factor-alpha (TNF-αa) gene in patients with prostate cancer
72. Preliminary evidence of an association of tumour necrosis factor microsatellites with increased risk of multiple basal cell carcinomas
73. Tumor necrosis factor a-11 and DR15-DQ6 (B × 0602) haplotype increase the risk for cervical intraepithelial neoplasia in human papillomavirus 16 seropositive women in Northern Sweden
74. Anti-cytokine therapy for rheumatoid arthritis
75. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
76. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
77. Anti-TNF antibody treatment of Crohn's disease
78. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-a therapy in rheumatoid arthritis
79. Reduction of serum matrix metalloproteinase 1 and matrix: Metalloproteinase 3 in RA patients following anti-TNFa (cA2) therapy
80. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor a blockade in patients with rheumatoid arthritis
81. Deactivation of vascular endothelium by monoclonal anti-tumour necrosis factor antibody in rheumatoid arthritis
82. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice
83. Biology of Cachexia
84. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice
85. Antitumor activity of thalidomide in refractory multiple myeloma
86. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
87. Aspirin use and risk of fatal cancer
88. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
89. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis